KALA BIO
KALA
59 hedge funds and large institutions have $160M invested in KALA BIO in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 15 closing their positions.
282% more call options, than puts
Call options by funds: $642K | Put options by funds: $168K
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
9% more funds holding
Funds holding: 54 → 59 (+5)
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7.83% less ownership
Funds ownership: 73.43% → 65.61% (-7.8%)
36% less capital invested
Capital invested by funds: $248M → $160M (-$88.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.03M |
| 2 |
GX
Greylock XII
Menlo Park,
California
|
+$2.44M |
| 3 |
BlackRock
New York
|
+$1.95M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.92M |
| 5 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TRV GP
Boston,
Massachusetts
|
-$22.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.41M |
| 3 |
BC
Broadfin Capital
New York
|
-$3.08M |
| 4 |
Millennium Management
New York
|
-$2.53M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.53M |
KALA Hedge Fund Activity: Q3 2018 in Review
59 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q3 2018, worth a combined $160M — down 36% from $248M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KALA positions and 15 closed out — a net gain of 5 holders — while 12 added to existing stakes and 11 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $5.03M. The largest seller was TRV GP, exiting entirely with an estimated $22.7M sold.
- 59 institutional investors held KALA BIO (KALA) as of Q3 2018, up from 54 in Q2 2018.
- Funds reported $160M of KALA BIO stock for Q3 2018, down 36% quarter-over-quarter.
- 20 funds opened new KALA BIO positions in Q3 2018 and 15 closed out, a net change of +5 holders.
- The largest KALA BIO buyer in Q3 2018 was T. Rowe Price Associates, an estimated $5.03M added.
- The largest KALA BIO seller in Q3 2018 was TRV GP, an estimated $22.7M sold.
Based on aggregated 13F filings for Q3 2018.